/NUVL
NUVL Stock - Nuvalent, Inc.
Healthcare|BiotechnologyNASDAQ
$103.80+2.36%
+$2.39 (+2.36%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.86
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+32.4%upside
Target: $137.43
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NUVL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$102.76 – $104.84
TARGET (TP)$137.44
STOP LOSS$95.50
RISK/REWARD1:4.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.31
52W High$112.88
52W Low$55.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-280,368,000 | $-149,492,000 | $-86,108,000 | $-45,817,000 | $-16,905,000 |
| Net Income | $-260,756,000 | $-126,219,000 | $-81,854,000 | $-46,338,000 | $-14,556,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.93 | $-2.17 | $-1.65 | $-2.13 | $-0.64 |
Company Overview
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
15
94%
Hold / Neutral
1
6%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
15 Bullish1 Neutral/Bearish
Price Targets
$93
Average Target
↓ 10.5% Downside
Now
$28
Low
$93
Average
$135
High
Based on 19 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| November 12th 2025 | Canaccord Genuity | Initiation | Buy | $126 |
| October 16th 2025 | Stifel | Resumed | Buy | $115 |
| October 15th 2025 | Cantor Fitzgerald | Initiation | Overweight | $135 |
| September 4th 2025 | Guggenheim | Resumed | Buy | $122 |
| September 3rd 2025 | Raymond James | Initiation | Outperform | $105 |
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $112 |
| March 14th 2025 | UBS | Upgrade | Buy | $100 |
| December 30th 2024 | H.C. Wainwright | Initiation | Buy | $110 |
| October 24th 2024 | UBS | Initiation | Neutral | $100 |
| August 29th 2024 | Barclays | Initiation | Overweight | $100 |
| April 17th 2024 | Jefferies | Initiation | Buy | $97 |
| April 1st 2024 | Leerink Partners | Upgrade | Outperform | $110← $69 |
| February 28th 2024 | Guggenheim | Resumed | Buy | $99 |
| February 23rd 2024 | Robert W. Baird | Initiation | Outperform | $105 |
Earnings History & Surprises
NUVLBeat Rate
28%
Last 18 quarters
Avg Surprise
-94.0%
EPS vs Estimate
Beats / Misses
5/12
1 met exactly
Latest EPS
$-1.70
Q4 2025
EPS Surprise History
Q1 24
-5.1%
$-0.62vs$-0.59
Q2 24
-3.0%
$-0.69vs$-0.67
Q3 24
-15.8%
$-0.88vs$-0.76
Q4 24
-37.0%
$-1.28vs$-0.93
Q1 25
-1.0%
$-1.05vs$-1.04
Q2 25
-3.5%
$-1.18vs$-1.14
Q3 25
-3.1%
$-1.31vs$-1.27
Q4 25
-22.3%
$-1.70vs$-1.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-1.51 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-1.39 | $-1.70 | -22.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.27 | $-1.31 | -3.1% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-1.14 | $-1.18 | -3.5% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-1.04 | $-1.05 | -1.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.93 | $-1.28 | -37.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.76 | $-0.88 | -15.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.67 | $-0.69 | -3.0% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.59 | $-0.62 | -5.1% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.59 | $-0.59 | 0.0% | = MET |
Q3 2023 | Aug 10, 2023 | $-0.53 | $-0.51 | +3.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.51 | $-0.44 | +13.7% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.43 | $-0.49 | -14.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.46 | $-0.41 | +10.9% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.43 | $-0.38 | +11.6% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.40 | $-0.36 | +10.0% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.32 | $-0.36 | -12.5% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.25 | $-0.39 | -56.0% | ✗ MISS |
Q3 2021 | Sep 8, 2021 | $-0.19 | $-3.17 | -1568.4% | ✗ MISS |
Q3 2021 | Jul 30, 2021 | — | $-0.30 | — | — |
Latest News
JP Morgan Maintains Overweight on Nuvalent, Lowers Price Target to $145
➖ NeutralBenzinga•Dec 19, 2025, 04:22 PM
Royalty Pharma Acquires Pre-Existing Royalty Interest In Nuvalent's Neladalkib And Zidesamtinib From Undisclosed Third Party For Up To $315M
📈 PositiveBenzinga•Dec 16, 2025, 12:16 PM•Also:
Truist Securities Initiates Coverage On Nuvalent with Buy Rating, Announces Price Target of $140
📈 PositiveBenzinga•Nov 24, 2025, 05:59 PM
Nuvalent New Drug Application For Zidesamtinib ROS1-Selective Inhibitor Reeives FDA's Approval To Treat Locally Advanced Or Metastatic Ros1-positive Non-small Cell Lung Cancer
📈 PositiveBenzinga•Nov 19, 2025, 09:22 PM
Reported Earlier, Nuvalent Prices Underwritten Offering Of 4,950,496 Class A Shares At $101 Each To Raise $500M
➖ NeutralBenzinga•Nov 19, 2025, 07:00 AM
Goldman Sachs Maintains Buy on Nuvalent, Raises Price Target to $135
📈 PositiveBenzinga•Nov 18, 2025, 05:51 PM
Baird Maintains Outperform on Nuvalent, Raises Price Target to $158
📈 PositiveBenzinga•Nov 18, 2025, 03:40 PM
Guggenheim Maintains Buy on Nuvalent, Raises Price Target to $155
📈 PositiveBenzinga•Nov 18, 2025, 02:56 PM
Nuvalent Announces $500M Class A Common Stock Offering
➖ NeutralBenzinga•Nov 17, 2025, 09:02 PM
Stifel Maintains Buy on Nuvalent, Raises Price Target to $135
📈 PositiveBenzinga•Nov 17, 2025, 05:47 PM•Also:
Nuvalent shares are trading higher after the company released topline data from its ALKOVE-1 Phase 1/2 trial and shared preliminary Phase 2 exploratory cohort results.
📈 PositiveBenzinga•Nov 17, 2025, 04:43 PM
HC Wainwright & Co. Maintains Buy on Nuvalent, Raises Price Target to $155
📈 PositiveBenzinga•Nov 17, 2025, 04:28 PM
Nuvalent Shared Topline Data From ALKOVE-1 Phase 1/2 Trial For Neladalkibin Pre-treated Patients With Advanced ALK-positive Non-small Cell Lung Cancer. Additionally, The Company Shared The First Report Of Preliminary Data From Phase 2 Exploratory Cohort
➖ NeutralBenzinga•Nov 17, 2025, 11:34 AM
Nuvalent shares are trading higher after the company announced it will present topline ALKOVE-1 trial data for Neladalkib on November 17.
📈 PositiveBenzinga•Nov 14, 2025, 09:15 PM
Nuvalent To Present Topline ALKOVE-1 Trial Data For Neladalkib On November 17, 2025 At 8:00am ET
➖ NeutralBenzinga•Nov 14, 2025, 09:04 PM
Canaccord Genuity Initiates Coverage On Nuvalent with Buy Rating, Announces Price Target of $126
📈 PositiveBenzinga•Nov 12, 2025, 12:06 PM•Also:
Nuvalent To Present Patient-Reported Outcomes Data From The Phase 2 Portion Of The ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And Encore Pivotal Efficacy And Safety Data From The ARROS-1 Trial At 2025 IASLC ASCO North America Conference On Lung Cancer
📈 PositiveBenzinga•Nov 4, 2025, 10:17 PM
UBS Maintains Buy on Nuvalent, Raises Price Target to $132
📈 PositiveBenzinga•Oct 31, 2025, 03:56 PM
Nuvalent Q3 EPS $(1.70) Misses $(1.36) Estimate
📉 NegativeBenzinga•Oct 30, 2025, 10:38 AM
Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128
📈 PositiveBenzinga•Oct 27, 2025, 01:13 PM
Frequently Asked Questions about NUVL
What is NUVL's current stock price?
Nuvalent, Inc. (NUVL) is currently trading at $103.80 per share. The stock has moved +2.36% today.
What is the analyst price target for NUVL?
The average analyst price target for NUVL is $137.44, based on 1 analyst.
What sector is Nuvalent, Inc. in?
Nuvalent, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NUVL's market cap?
Nuvalent, Inc. has a market capitalization of $7.55 billion, making it a mid-cap company.
Does NUVL pay dividends?
No, Nuvalent, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to NUVL for comparison